

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Maiva Pharma opens sterile injectable manufacturing facility in Tamil Nadu

08 June 2026 | News

Six manufacturing lines to enable production of diverse sterile injectable formats



Maiva Pharma, a leading global Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO) specialising in sterile injectables, has inaugurated its new manufacturing facility at Shoolagiri, Tamil Nadu, India.

The facility marks a significant milestone in Maiva's growth journey, further strengthening its position as a trusted partner to global pharmaceutical and biotechnology companies for the development and manufacturing of generic and complex sterile injectable products.

Spread across a 22-acre site, the new facility has been designed to support current and future market requirements through advanced manufacturing technologies, flexible production capabilities, and world-class quality systems.

Upon full development, the facility will house six manufacturing lines capable of producing a broad range of sterile injectable dosage forms, including vials, pre-filled syringes (PFS), cartridges, suspension products, and lyophilised formulations.

As part of the Phase 1 expansion, Maiva Pharma has commissioned three dedicated manufacturing lines comprising a high-speed vial filling line, a combined pre-filled syringe and cartridge line, and a lyophilisation line. The facility is further supported by advanced Quality Control chemical laboratories and state-of-the-art Microbiology laboratories, enabling comprehensive analytical testing and quality assurance functions in-house.

A key highlight of the facility is its advanced isolator-based manufacturing lines for liquid vials, pre-filled syringes, cartridges, and lyophilised vials. The isolator technology enhances sterility assurance, operational efficiency, and manufacturing flexibility while supporting the production of a wide range of injectable products for regulated global markets.